Resmed Inc

Resmed Inc(RMD)の株式分析

$238.970

-3.226 (-1.35%)終値時点

Loading chart…
高値
242.575
始値
241.540
出来高加重平均価格
239.80
出来高
2.55M
時価総額
28.14B
安値
237.870
売買代金
610.71M
EV/EBITDA(TTM)
15.49

ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.

www.resmed.com

AI分析 of Resmed Inc (RMD)

買い

ResMed Inc. is a good buy right now due to its current price of $238.97 being below the analyst price targets of $262 and $267, indicating significant upside potential. The stock has shown a strong RSI of 72.818, suggesting bullish momentum, and a solid gross margin of 58.12%, indicating good profitability. However, the recent insider selling by the CEO, who sold nearly 5,000 shares, may raise concerns about future performance, which is a risk to consider.

アナリスト評価(10)

上値余地 +23.03%
買い
4 買い
2 中立
4 売り
現在: 238.97
安値
260.00
平均
294.00
高値
345.00

RBC Capital

2026-09-15

目標株価

$262

アウトパフォーム

Citi

2026-09-10

目標株価

$240

中立

KeyBanc

2026-08-31

目標株価

$267

オーバーウェイト

Rothschild & Co Redburn

2026-08-19

目標株価

$230

中立

RBC Capital

2026-08-07

目標株価

$244

Sector Perform

バリュエーション指標

Resmed Inc(RMD)の現在の予想PERは18.52で、5年平均は25.85です。

予想PER

適正
5年平均 P/E
25.85
現在のP/E
18.52
割高
34.14
割安
17.55

予想EV/EBITDA

適正
5年平均 EV/EBITDA
19.60
現在のEV/EBITDA
15.49
割高
24.23
割安
14.97

予想PSR

適正
5年平均 P/S
6.73
現在のP/S
5.49
割高
8.04
割安
5.42

Alphio AI による RMD の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%RMD

$284.42

シナリオ価格

基

基本

基本 · 50%RMD

$251.26

シナリオ価格

弱

弱気

弱気 · 25%RMD

$215.34

シナリオ価格

RMD を保有するクジラ

W

Walter Scott & Partners Limited

+ を保有RMD

+6.20%

3か月リターン

W

Welch & Forbes LLC

+ を保有RMD

+4.44%

3か月リターン

A

American Capital Management, Inc.

+ を保有RMD

+1.32%

3か月リターン

G

Giverny Capital Inc.

+ を保有RMD

+1.23%

3か月リターン

T

The MassMutual Trust Company, F.S.B., Trust Investments

+ を保有RMD

+0.04%

3か月リターン

I

Ilex Capital Partners (Uk) LLP

+ を保有RMD

-0.03%

3か月リターン

イベントタイムライン

2026-09-01 (ET)

09:00:00

Resmed Completes Sale of MatrixCare to Frazier Healthcare

2026-08-06 (ET)

19:00:00

Stock Futures Mixed as Doximity Soars 83.93%

16:30:00

Resmed Reports Q4 Revenue of $1.46B

16:30:00

ResMed Increases Quarterly Dividend by 10% to 66 Cents

ニュース

RMD のよくある質問 — Alphio AI が回答

ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

ResMed Inc. is a good buy right now due to its current price of $238.97 being below the analyst price targets of $262 and $267, indicating significant upside potential. The stock has shown a strong RSI of 72.818, suggesting bullish momentum, and a solid gross margin of 58.12%, indicating good profitability. However, the recent insider selling by the CEO, who sold nearly 5,000 shares, may raise concerns about future performance, which is a risk to consider.

10 analysts cover RMD: 4 rate it Buy, 2 Hold and 4 Sell. The average price target is 294.00.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める